Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Lipids Help to Fight Leukemia

16.06.2014

T cells use a novel mechanism to fight leukemia.

They may recognize unique lipids produced by cancer cells and kill tumor cells expressing these lipid molecules. A study conducted by researchers at the University of Basel shows that a tumor-associated lipid stimulates specific T cells, which efficiently kill leukemia cells both in vitro and in animal models. The results have been published in the Journal of Experimental Medicine.

Leukemias are cancer diseases affecting blood cells . Acute leukemias prevent development of normal bold cells and thereby are severe life-threatening diseases. Current therapy for acute leukemias is based on chemotherapy that eradicates tumor cells followed by bone-marrow stem cell transplantation that reconstitutes the patient with healthy blood cells. In some cases, leukemia cells survive this treatment and start to re-grow. A major aim of many studies is finding novel and efficient ways to detect and eradicate leukemia cells before a second outbreak of the disease.

More punch against tumor cells

T lymphocytes are major contributors to fight against leukemias. T cells may recognize and become activated by tumor-specific protein antigens in some instances produced in large amounts only by tumor cells. These protein antigens are also called tumor-associated antigens (TAA) and stimulate specific T cells, which in turn kill leukemia cells. However, protein TAA accumulation can be drastically reduced by variant leukemia cells and some TAA may change their structure, thus preventing recognition by T cells and facilitating tumor immune evasion.

Prof. Gennaro De Libero and his team from the Department of Biomedicine at the University of Basel has identified a new approach that might help to make the immune system more efficient in recognizing leukemia cells. His research team is studying T cells that specifically recognize lipid antigens since several years. Together with colleagues in Italy, China and Singapore, the Swiss team has identified a new lipid that accumulates in leukemia cells and that stimulates specific T cell responses. The new lipid methyl-lysophosphatidic acid (mLPA) is very abundant in several forms of human leukemias and is the first example of a lipid TAA.

Therapeutic implications in human leukemia

The published study also shows that it is possible to isolate human T cells that specifically recognize and kill mLPA-expressing leukemia cells in in vitro tests. When these T cells were transplanted into mice, they also displayed great in vivo therapeutic efficacy against leukemia cells.

An important feature of mLPA is that differently from protein TAA, it does not change its structure, and remains abundant in leukemia cells. The Swiss team is now investigating, whether mLPA can be used to target leukemia cells in addition to protein TAA. This type of immunotherapy may be extremely beneficial in preventing relapses of the disease after chemotherapy and bone marrow transplantation. It opens new avenues to novel non-invasive cancer immunotherapies.

Original source
Marco Lepore, Claudia de Lalla, S. Ramanjaneyulu Gundimeda, Heiko Gsellinger, Michela Consonni, Claudio Garavaglia, Sebastiano Sansano, Francesco Piccolo, Andrea Scelfo, Daniel Häussinger, Daniela Montagna, Franco Locatelli, Chiara Bonini, Attilio Bondanza, Alessandra Forcina, Zhiyuan Li, Guanghui Ni, Fabio Ciceri, Paul Jenö, Chengfeng Xia, Lucia Mori, Paolo Dellabona, Giulia Casorati, and Gennaro De Libero
A novel self-lipid antigen targets human T cells against CDc+ leukemias
The Journal of Experimental Medicine (2014) | doi: 10.1084/jem.20140410

Further information
• Prof. Gennaro De Libero, University of Basel, Department of Biomedicine, phone: +41 61 265 23 65, email: gennaro.delibero@unibas.ch
• Dr. Lucia Mori, University of Basel, Department of Biomedicine, phone: +41 61 265 23 27, email: lucia.mori@unibas.ch

Weitere Informationen:

http://www.jem.org/cgi/doi/10.1084/jem.20140410 - Abstract

Reto Caluori | Universität Basel
Further information:
http://www.unibas.ch

Further reports about: Lipids Medicine chemotherapy diseases leukemia structure

More articles from Life Sciences:

nachricht 127 at one blow...
18.01.2017 | Stiftung Zoologisches Forschungsmuseum Alexander Koenig, Leibniz-Institut für Biodiversität der Tiere

nachricht How gut bacteria can make us ill
18.01.2017 | Helmholtz-Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Explaining how 2-D materials break at the atomic level

18.01.2017 | Materials Sciences

Data analysis optimizes cyber-physical systems in telecommunications and building automation

18.01.2017 | Information Technology

Reducing household waste with less energy

18.01.2017 | Ecology, The Environment and Conservation

VideoLinks
B2B-VideoLinks
More VideoLinks >>>